Effect of Lipo-PGE1 on health-related quality of life in patients with systemic sclerosis and systemic lupus erythematosus in Japan

Journal of International Medical Research

Volumn 36, Issue 1, 2008, Pages 187-197

  Hoshi, K ^a,c   Fukuhara, S ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Clinical symptoms; Cutaneous ulcers; Health related quality of life; Lipo PGE1; Prostaglandin; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; LIPOPROSTAGLANDIN E1; STEROID; VASODILATOR AGENT; VITAMIN B GROUP; PROSTAGLANDIN E1;

ADULT; AGED; ARTHRITIS; ARTICLE; COUGHING; EDEMA; ESOPHAGUS DISEASE; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; INTESTINAL DYSMOTILITY; JAPAN; KIDNEY DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NEPHRITIS; PAIN; PHYSICAL CAPACITY; QUALITY OF LIFE; SHORT FORM 36; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; CLINICAL TRIAL; DAILY LIFE ACTIVITY; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MENTAL HEALTH; MIDDLE AGED; PAIN; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; SKIN ULCER;

EID: 39149105975     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600124     Document Type: Article

References (15)

1. 1 is more effective, when incorporated in lipid micro spheres, for treatment of peripheral vascular disease in man. J Pharm Pharmacol 1983; 35: 666-667.
2. Mizushima Y: Lipid micro spheres as novel drug carriers. Drugs Exp Clin Res 1985; 11: 595-600.
3. 1 in Japan. Adv Drug Deliv Rev 1996; 20: 171-176.
4. Ware JE, Sherboune DC: The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-489.
5. Stewart AL, Ware JE: Measuring Functioning und Well-being. The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.
6. McHorney CA, Ware JE, Raczek AE: The MOS 36-item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263.
7. McHorney CA, Ware JE, Rachel Lu JF, et al: The MOS 36-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
8. Fukuhara S, Bito S, Green J, et al: Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 1037-1044.
9. Fukuhara S, Suzukamo Y: Manual of SF-36 V2 Japanese Version. Kyoto: Institute for Health Outcomes & Process Evaluation Research, 2004.
10. Bito S, Fukuhara S, Green J, et al: Comorbidity and health-related quality of life (abstract). Qual Life Res 1997; 6: 43.
11. Fukuhara S, Ware JE, Kosinski M, et al: Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045-1053.
12. Nakamura K, Sakata K, Fujita I, et al: Epidemiological features of medicare recipients under the program to subsidize medical cost for intractable diseases. Jpn J Public Health 1991; 38: 525-533 [in Japanese].
13. 1 in the treatment of peripheral circulatory involvement associated with collagen diseases. Jpn J Inflamm 1986; 6: 83-93.
14. 1 on chronic arterial occlusive disease - essentially health-related QOL (SF-36). Jpn J Vasc Surg 2003; 12: 571-580.
15. Fukuhara S, Esato K: The effect of Liple® on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. Int Angiol 2004; 23: 238-245.